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For many years, sorafenib has been the only approved systemic 
treatment for advanced hepatocellular carcinoma (HCC). For 
over a decade, randomized controlled trials exploring the 
efficacy of new drugs both in first- and second-line treatment 
have failed to prove any survival benefit. However, in the past 
few years, several advances have been made especially in 
pretreated patients; phase III trials of regorafenib, cabozantinib, 
and ramucirumab in patients with elevated α-fetoprotein have 
demonstrated efficacy in patients progressing after or intolerant 
to sorafenib. In addition, early phase I and II trials have shown 
promising results of immunotherapy alone or in combination 
with tyrosine-kinase inhibitors or monoclonal antibodies in 
the same setting of patients. In this review, we will discuss the 
evidence on second-line options for HCC, focusing on the latest 
results that are currently refining the treatment scenario.
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Introduction
Hepatocellular carcinoma (HCC) is the most frequent primary 
liver tumor, and it is a worldwide leading cause of morbidity 
and mortality. According to recent statistics, about 40,000 HCC 
new cases and 30,000 deaths are expected in the United States 
alone in 2018.1
Chronic liver inflammation is a procarcinogenic condition 
that is associated to the majority of known HCC risk factors: 
hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol abuse/
exposure to toxic agents, nonalcoholic fatty liver disease 
(NAFLD), and autoimmune hepatitis. In 30% of cases, no 
risk factor is identified and HCC is defined as cryptogenetic; 
however, it is important to point out that many of these risk 
factors are preventable (such as HBV infection prevented by 
active vaccination) or can be handled with habit modifications 
(alcohol abuse and nonalcoholic steatohepatitis [NASH] that 
is a precursor of NAFLD) or with effective treatment (direct-
acting antiviral agents for HCV infection).2 Although this should 
hopefully lead to a drastic change in the epidemiology of HCC 
in the next decades, HCC currently remains a major health 
problem worldwide.3
Sorafenib, a multi-target tyrosine-kinase inhibitor (TKI), was 
the first drug to demonstrate efficacy in advanced HCC with 
well-preserved liver function (Child-Pugh A). Ten years ago, in 
the SHARP randomized trial and afterward in the Asia-Pacific 
randomized trial, the comparison of sorafenib to placebo led 
to a significant improvement in overall survival (OS) and time 
to progression (TTP).4,5 The drug was consequently approved 
for the treatment of advanced disease, and has remained the 
gold standard for over a decade. After the negative results 
of several randomized controlled trials (RCTs),6–10 in 2018 
lenvatinib has proved to be noninferior to sorafenib in the 
first-line setting11 and has subsequently received approval by 
Food and Drugs Administration (FDA) and European Medicines 
Agency (EMA).12,13
Unfortunately, both adaptive resistance and intrinsic resistance 
represent crucial issues in the management of patients 
receiving first-line treatment of HCC. Disease progression or 
significant toxicity leading to first-line therapy discontinuation 
is a frequent event and further treatment options are eagerly 
needed. Disappointingly, the first attempt to provide a gold 
standard in the second-line treatment was unsuccessful.
We performed a structured search on the PubMed database 
and on the proceedings of the main oncology and hepatology 
conferences, identifying clinical trials of second-line therapy 
in HCC between 1 January 2008 and 15 February 2019. We 
also searched Clinicaltrials.gov with the terms ‘hepatocellular 
carcinoma’ and ‘liver cancer’ to identify ongoing post-sorafenib 
clinical trials.
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Hence, in this review, we will discuss the evidence on second-
line options for HCC, focusing on the latest results that are 
currently refining the treatment scenario.
Negative randomized control trials
Following the publication of the SHARP trial and based on 
promising phase II trials, several drugs have been tested in RCTs 
in patients experiencing failure of first-line sorafenib. In these 
trials, given the absence of an active standard treatment, TKIs 
or monoclonal antibodies (MoAbs) with different target profile 
were compared to placebo and best supportive care (BSC).
Brivanib
Brivanib is an oral inhibitor of vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF) receptor that 
was tested in HCC patients both in first-line and in second-line 
therapy.7,14 In the BRISK-PS study, 395 patients with advanced 
HCC progressing on or intolerant to sorafenib were enrolled. 
Despite a benefit in TTP (median TTP was 4.2 months for 
brivanib and 2.7 months for placebo; p<0.001) and objective 
response rate (ORR) (10 and 2%, respectively) assessed with 
mRECIST criteria, there was no significant improvement in 
OS; median OS was 9.4 months for brivanib and 8.2 months 
for placebo (hazard ratio [HR] 0.89; 95.8% confidence interval 
[CI]: 0.69–1.15; p=0.3307). The authors indicated numerical 
imbalances in some baseline factors such as α-fetoprotein (AFP) 
levels and the presence of vascular invasion, favoring placebo as 
possible explanation for brivanib failure.
Everolimus
On the basis of preclinical evidence supporting the role of the 
mTOR pathway in hepatocarcinogenesis and of the clinical 
experience of the mTOR inhibitor everolimus in HCC, the phase 
III trial EVOLVE-1 was designed.15 It enrolled 546 patients with 
advanced HCC whose disease progressed during or after 
sorafenib or who were sorafenib intolerant. The patients were 
randomized in a 2:1 ratio to receive everolimus 7.5 mg per 
day (n=362) or matched placebo (n=184). The treatment with 
everolimus did not confer any survival advantage: mOS 7.6 
months for everolimus and 7.3 months for placebo (HR 1.05; 
95% CI: 0.86–1.27; p=0.68). Prespecified subgroup analyses 
revealed similar results in most subgroups, except for HBV-
positive patients who seemed to obtain some benefit from 
everolimus therapy. However, no differences were seen in 
secondary endpoints such as TTP, disease control rate (DCR), 
and health-related quality of life (HR-QoL).
Ramucirumab
Ramucirumab, a recombinant IgG1 MoAb directed against 
VEGFR-2, was tested as second-line treatment in the REACH 
trial, enrolling 565 HCC patients.16 Inclusion criteria and 
study design were similar to the RCTs already discussed. In 
this study population, ramucirumab achieved better TTP 
(median 3.5 versus 2.6 months; p<0.0001), ORR (7 versus 
<1%; p<0.0001), and DCR (56 versus 46%; p=0.011) at the 
cost of manageable toxicities. However, the primary endpoint 
was not met: mOS 9.2 months in the ramucirumab group 
compared with 7.6 months in the placebo group (HR 0.87; 95% 
CI: 0.72–1.05; p=0.14). In the prespecified subgroup analyses, 
patients with a baseline AFP concentration of 400 ng/mL or 
greater had a statistically significant survival benefit (mOS 
7.8 versus 4.2 months; HR 0.67; 95% CI: 0.51–0.90; p=0.006). 
This subgroup also experienced a benefit from ramucirumab 
treatment in the deterioration of symptoms in FHSI-8 (HR 0.690; 
p=0.054) and PS (HR 0.642; p=0.057).17 These findings have 
led to the design of a population-enriched trial that will be 
discussed later.
ADI-PEG 20
ADI-PEG 20 is the pegylated form of the enzyme arginine 
deiminase (ADI) that converts arginine to citrulline. Arginine 
deprivation can induce HCC cell death, and it is therefore a 
potential target for cancer treatment. The development of 
ADI-PEG 20 has moved fast from phase II 18 to a phase III trial 
that enrolled 635 patients worldwide.19 Unfortunately, similar to 
the previously listed studies, this trial did not reach its primary 
endpoint: mOS was 7.8 months for ADI-PEG 20 versus 7.4 months 
for placebo (HR 1.022; 95% CI: 0.847–1.233; p=0.884). Despite these 
negative results in the whole study population, post hoc analyses 
suggested improved survival in patients with prolonged arginine 
depletion (mOS 12.3 versus 7.3 months; p=0.0032) or citrulline 
increase (mOS 11.6 versus 3.5 months; p<0.0001) for >8 weeks.
Tivantinib
In the METIV-HCC trial, tivantinib, a selective TKI targeting MET 
receptor, was tested in a biomarker-enriched population.20 
The HGF-MET pathway is involved in tumor development and 
metastasis and has a prognostic value. Moreover, MET is often 
overexpressed after sorafenib exposure. In a randomized phase 
II trial, interesting hints of efficacy of tivantinib were seen in 
MET-high tumors21; therefore, only patients harboring this 
molecular characteristic (staining intensity score ≥2 in ≥50% 
of tumor cells) were enrolled in the subsequent randomized, 
double-blind, placebo-controlled trial. Unfortunately, efficacy 
outcomes were not significantly different between the groups, 
and the trial did not meet its primary endpoint (mOS was 8.4 
months for tivantinib and 9.1 months for placebo; HR 0.97; 
95% CI: 0.75–1.25; p=0.81). Although it is difficult to identify a 
clear reason for such a negative result, authors suggest that 
it may be due to the tivantinib formulation (capsules in the 
phase II study and tablets in the phase III study), different 
timing of tissue analysis (before sorafenib exposure or after 
sorafenib progression), unintentional selection of patients with 
less-aggressive disease, and importance of maintaining VEGF 
inhibition beyond first-line treatment. The lack of efficacy on 
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benefit of regorafenib treatment was consistent for primary 
and secondary endpoints and in all prespecified subgroup 
analyses. Namely, mOS was 10.6 months with regorafenib 
and 7.8 months with placebo (HR 0.63; 95% CI: 0.50–0.79; 
p<0.0001). In addition, mTTP by mRECIST was 3.2 months 
with regorafenib and 1.5 months with placebo and more 
patients in the experimental arm experienced disease control 
(DCR 65 versus 36%; p<0.0001). As for safety, more patients 
in the regorafenib arm had treatment interruptions or dose 
reductions (54 versus 10%) and discontinuation due to drug-
related adverse events (10 versus 4%); however, no difference 
in grade 5 adverse events was recorded. HR-QoL was assessed 
using FACT-G, FACT-Hep, EQ-5D, and EQ-VAS questionnaires; 
globally, the scores were similar between the groups except 
for the FACT-Hep total score that favored placebo (p<0.001). 
Nevertheless, the difference did not meet the established 
minimally important threshold of 8–9 points (129.31 points 
for regorafenib and 133.17 points for placebo).25 The adverse 
events profile of regorafenib in this study is in line with the 
known drug safety profile from other indications, being 
hypertension (15%), HSFR (9%), and diarrhea (3%) the most 
common clinically relevant grade 3 or 4 events.
Based on the results of the RESORCE trial, regorafenib was the 
first drug to be approved by regulatory agencies as second-
line treatment for HCC patients following first-line sorafenib. 
Subsequent analyses showed that, at least in this selected 
population of patients who well tolerated sorafenib and were 
subsequently eligible for a second-line treatment, the sequence 
sorafenib-regorafenib yields a mOS of 26 months versus 19.2 
months of sorafenib-placebo, and that the survival benefit is 
independent of the pattern of the disease progression during 
prior sorafenib treatment and of their last sorafenib dose (800 
or <800 mg/day).26 The development of new distant metastases 
or vascular invasion was confirmed to be associated with 
worse survival irrespective of treatment.27 Similar to previous 
observation with sorafenib, also for regorafenib treatment the 
early onset of dermatological toxicity correlates with better 
outcome.28 As for molecular biomarkers, regorafenib benefit is 
independent of baseline AFP and cMET protein levels that are 
on the contrary negative prognostic factors.29 Initial evidence 
suggests that some single-nucleotide polymorphisms (SNPs) 
assessed in the RESORCE population may have a prognostic 
and predictive impact: however, to date, no predictive 
molecular biomarker of regorafenib benefit has been 
established.30
Cabozantinib
Cabozantinib is an oral multitarget TKI that was initially 
identified as a potent dual inhibitor of VEGFR-2 and c-MET. Its 
target profile also includes the inhibition of VEGFR-1 and 3, AXL, 
RET, FLT3, and TIE-2. It is important to point out that both MET 
and AXL overexpression has a negative prognostic impact and 
that MET might be induced by sorafenib treatment and can 
be a mechanism of resistance.31,32 The first clinical experience 
tivantinib in HCC treatment was also confirmed in the Japanese 
population enrolled in the phase III trial JET-HCC.22
Regorafenib
Regorafenib is an oral multitarget inhibitor that is already 
approved for refractory colorectal cancer and gastrointestinal 
stromal tumors (GISTs). Although it is structurally similar to 
sorafenib, regorafenib shows a more potent pharmacological 
activity and a distinct molecular target profile, blocking the 
activity of several protein kinases involved in the regulation 
of tumor angiogenesis (VEGFR1, VEGFR2, VEGFR3, and TIE2), 
oncogenesis (KIT, RET, RAF1, BRAF, and BRAFV600E), and the 
tumor microenvironment (PDGFR and FGFR). In a single-arm 
phase II trial, 36 patients with Barcelona Clinic Liver Cancer 
(BCLC) staging classification B or C HCC that would not benefit 
from treatments of established efficacy were enrolled.23 
Notably, patients who experienced discontinuation of previous 
sorafenib due to poor drug tolerability were excluded. The 
primary endpoint of the study was to assess the safety of 
regorafenib as second-line treatment in HCC patients who 
had disease progression after sorafenib; secondary endpoints 
included efficacy (including TTP and OS) and pharmacokinetics. 
In half of the cases, adverse events were the reasons for 
treatment discontinuation, but only in 19% it was deemed to 
be related to regorafenib. All the 36 patients experienced at 
least a treatment-related adverse event, and dose modifications 
were frequent (97%); nevertheless, the safety profile in this 
setting of patients was in line with the known safety from other 
indications, and it was globally deemed manageable, being 
diarrhea, fatigue, and hand–foot skin reaction (HFSR) the most 
frequent adverse events. Notably, in the efficacy analysis, mTTP 
was 4.3 months (95% CI: 2.9–13.1) and mOS was 13.8 months 
(95% CI: 9.3–18.3) with a DCR of 72%. On these bases, the drug 
was moved to a phase III RCT, the RESORCE study,24 that was 
planned as a double-blind, placebo-controlled, international 
trial. Randomization was stratified by geographical region 
(Asia versus rest of world), macrovascular invasion (yes versus 
no), extrahepatic disease (yes versus no), AFP concentration 
(<400 versus ≥400 ng/mL), and Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) (0 versus 1). As for the 
phase II study, eligible patients must have a BCLC stage B or C 
not amenable to locoregional treatments, a Child-Pugh A, and 
they had to be previously treated with sorafenib in first-line 
treatment. To select a study population that could more likely 
tolerate regorafenib, patients needed to be sorafenib-tolerant, 
meaning that they must have received ≥400 mg of sorafenib 
daily for at least 20 of the 28 days preceding discontinuation. 
As a consequence, all the patients enrolled in the RESORCE trial 
had discontinued sorafenib because of disease progression. 
The drug was administered at the recommended dosing 
schedule of 160 mg once daily in repeating cycles of 3 weeks 
on treatment followed by 1 week off treatment and the 
treatment needed to be initiated within 10 weeks of sorafenib 
discontinuation. After a median follow-up of 7 months, the 
Marino D, Zichi C, Audisio M, Sperti E, Di Maio M. Drugs in Context 2019; 8: 212577. DOI: 10.7573/dic.212577 4 of 13
ISSN: 1740-4398
REVIEW – Second-line therapy in HCC drugsincontext.com
of cabozantinib in HCC involved 41 patients (19 sorafenib 
naïve, 22 sorafenib pretreated) enrolled in 1 of the 9 cohorts 
of a phase II randomized discontinuation trial.33,34 Patients 
received a 12-week lead-in treatment with 100 mg per day of 
cabozantinib. After restaging, patients with stable disease (SD) 
were randomized to cabozantinib or placebo, patients with a 
partial response (PR) could continue open-label cabozantinib 
treatment, and patients with progressive disease (PD) at or 
before week 12 permanently discontinued treatment. The 
primary endpoint of the lead-in phase was ORR at week 12, 
and the primary endpoint of the randomized phase was PFS. 
Randomization was halted before the preplanned accrual 
was reached due to initial efficacy results. In the HCC cohort, 
cabozantinib demonstrated a week-12-ORR of 5% and a week-
12-DCR of 66%. Among the patients who had SD at week 12 
(n=22), 12 patients were randomized to placebo and 10 to 
cabozantinib. With the limitation of this small sample size, 
no significant difference in PFS was observed between the 
two groups. In the overall population of 41 treated patients, 
mPFS from the start of the study was 5.2 months and mOS 11.5 
months. The most frequent adverse events (diarrhea, weight 
loss, and HFSR) were mainly mild to moderate.
Based on these preliminary signals of clinical activity, a phase 
III, randomized, double-blind, controlled trial comparing 
cabozantinib to placebo in patients with HCC who had 
received prior sorafenib therapy was conducted (the CELESTIAL 
trial).35 Study treatment accounted for either a 60-mg of 
cabozantinib or a matched placebo once per day administered 
as long as patients experienced clinical benefit, or until they 
had unacceptable toxicity. Patients were allowed to receive 
cabozantinib or placebo beyond radiographic progression, as 
long as they continued to have clinical benefit. Randomization 
was stratified according to etiologic factor (HBV+HCV versus 
HCV without HBV versus other), geographic region (Asia versus 
other), and evidence of extrahepatic disease, macrovascular 
invasion, or both (yes versus no). Eligible patients had a 
diagnosis of HCC not amenable to curative treatment but 
with preserved liver function (Child-Pugh A) and had received 
previous sorafenib, but they could have received up to two 
previous systemic treatments and should have progressed 
on at least one of them (27% of cases). A total of 707 patients 
were randomized, in a 2:1 ratio, to receive cabozantinib (470), 
or placebo (237) in 95 centers worldwide during 4 years. 
The trial reached its primary endpoint of improving survival 
at the second preplanned interim analysis: median OS was 
10.2 months in the cabozantinib group and 8.0 months in 
the placebo group (HR for death 0.76; 95% CI: 0.63–0.92; 
p=0.005). In the subgroup of patients whose only previous 
systemic therapy was sorafenib, the mOS was 11.3 months 
with cabozantinib and 7.2 months with placebo (HR for death 
0.70; 95% CI: 0.55–0.88). In addition, the secondary endpoints 
favored the experimental arm; cabozantinib yielded a DCR 
of 64% as compared with 33% in the placebo group. mPFS 
was 5.2 months in the cabozantinib group and 1.9 months 
in the placebo group (HR 0.44; 95% CI: 0.36–0.52; p<0.001). 
Of note, 47% of patients on cabozantinib had a reduction in 
target lesions, and 23% of AFP-high patients on cabozantinib 
experienced ≥50% reduction in AFP levels.36,37 Overall, patients 
with AFP levels >400 ng/mL experienced a larger treatment 
benefit from cabozantinib if compared with those with AFP 
<400 ng/mL (HR for OS 0.71 versus 0.81). Other analyses have 
shown that the benefit of cabozantinib is independent of the 
presence of macrovascular invasion, extrahepatic disease, 
disease extension, previous TACE treatment, and age (<65 or 
≥65 years).38–40
As for safety, more patients in the experimental arm needed 
dose reductions (62 versus 13%) or treatment discontinuation due 
to drug-related adverse events (16 versus 3%). Adverse events 
were consistent with the known safety profile of the drug, being 
the most common grade 3 or 4 adverse events palmar–plantar 
erythrodysesthesia (17 versus 0% with placebo), hypertension 
(16 versus 2%), increased aspartate aminotransferase (AST) level 
(12 versus 7%), fatigue (10 versus 4%), and diarrhea (10 versus 
2%). HR-QoL was assessed using the EQ-5D-5L questionnaire at 
baseline, every 4 weeks through week 25, then every 8 weeks, 
but these results have not been reported yet. Based on the 
CELESTIAL trial results, cabozantinib has been approved by 
the EMA for the treatment of patients previously treated with 
sorafenib and is under evaluation by the FDA.
Ramucirumab
We have already discussed the initial clinical development 
of the MoAb ramucirumab in HCC. Following the results of 
the REACH trial16 in the subgroup of patients with baseline 
AFP concentration of 400 ng/mL or greater, the REACH-2 
trial was designed to assess the benefit of ramucirumab 
specifically in this subgroup of patients. The results of this trial 
were presented at the 2018 ASCO Meeting.41 There were 292 
previously treated patients with BCLC-B or C HCC, Child-Pugh 
A who were randomized 2:1 to receive ramucirumab 8 mg/kg 
(n=197) or matched placebo (n=95) intravenously (I.V.) every 
2 weeks. Treatment was continued until PD or unacceptable 
toxicity, and patients were stratified according to macrovascular 
invasion (yes versus no), ECOG PS (0 versus 1), and geographic 
region (Japan versus rest of Asia versus other regions). The 
primary endpoint of the study was OS, and the secondary 
objectives included PFS, ORR per RECIST v1.1, and safety.
In the efficacy analysis, OS benefit favored ramucirumab over 
placebo: mOS was 8.5 versus 7.3 months (HR for death 0.71; 
p=0.0199). Secondary endpoints were improved as well; mPFS 
was 1.6 months in the placebo arm and 2.8 months in the 
ramucirumab arm (p<0.0001), and DCR was 38.9 and 59.9%, 
respectively (p=0.0006). Although the absolute benefit seems 
inferior if indirectly compared to the other studies we have 
already discussed, it is important to point out that elevated 
AFP is a recognized negative prognostic factor in HCC and 
consequently patients included in the REACH-2 trial had 
per se a worse survival expectancy. In addition, for the first 
time in the clinical development of a drug in this disease, a 
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predictive marker of response (AFP≥400 ng/mL) was validated. 
Ramucirumab toxicity was globally manageable with no 
unexpected adverse events recorded. The most common 
grade ≥3 adverse events of interest were hypertension (12.7%), 
bleeding events (5.1%), proteinuria (2%), and liver injury (18.3%).
Data from the REACH-2 and from the AFP-high patients 
enrolled in the REACH trial were recently pooled together.42 In 
a population of 542 patients (292 patients from the REACH-2 
and 250 patients from the REACH trial), 316 were treated with 
ramucirumab and 226 with placebo. The results of the pooled 
analysis are consistent with the individual studies, with a 
significant improvement in survival favoring ramucirumab 
(median OS 8.1 months versus 5.0  months; HR 0.694; p=0.0002). 
Improvements in PFS (mPFS 2.8  months versus 1.5  months; 
HR 0.572; p<0.0001), ORR (5.4 versus 0.9%; p=0.0040), and DCR 
(56.3 versus 37.2%; p<0.0001) were observed. In another recent 
analysis on patients reported outcomes assessed in the same 
pooled population, ramucirumab demonstrated a consistent 
trend for a benefit in disease-related symptoms as measured by 
FACT-FHSI-8.43
The results of phase III trials in second-line treatment for HCC 
are summarized in Table 1.
Immunotherapy and future 
perspectives
Immunotherapy has been the breakthrough in cancer 
treatment in the last few years, and it has completely 
revolutionized the cure strategy, with continuous advances and 
evidence of efficacy in several types of cancer. The possibility 
of unleashing T cells activation against cancer cells produces 
durable responses at the cost of limited toxicity. Although 
the knowledge of predictive factors is far from being optimal, 
efficacy of immunotherapy is often correlated to specific 
features that are independent of the site of primary tumor, such 
as PD-1/PD-L1 expression, tumor mutational burden (TMB), or 
presence of microsatellite-instable phenotype (MSI-H).44–46 
In HCC etiology, the role of chronic liver injury is prevalent 
and it is associated with inflammation and establishment of a 
suppressed immune environment. In addition, high expression 
of PD-L1 in tumors correlates with a poorer prognosis in 
patients with HBV-related HCC, and upregulation of PD-1 on 
CD8(+) T cells could predict a poorer disease progression and 
postoperative recurrence.47,48 Within HCC, current evidence 
suggests the presence of three immunogenic subgroups that 
show different patterns of immune cell infiltration, PD-1/PD-
L1 expression, IFNγ signaling activation, and chromosomal 
aberrations and may consequently show a different potential 
of response to immunotherapy.49 Currently, clinical evidence of 
efficacy of immunotherapy in HCC is available for two anti-PD-1 
MoAbs, nivolumab and pembrolizumab.
Nivolumab
The CheckMate-040 was designed as a multicenter, open-
label, phase I/II study, to evaluate the safety and efficacy 
of nivolumab in 262 patients with advanced HCC.50 Eligible 





Patients (n) Survival 
(months)
Significance TTP or PFS* 
(months)
Significance
BRISK-PS Llovet et al.14 Brivanib versus 
placebo
A-B7 263 versus 132 9.4 versus 8.2 p=0.33 4.2 versus 2.7 p=0.001
EVOLVE-1 Zhu et al.15 Everolimus 
versus placebo
A 362 versus 184 7.6 versus 7.3 p=0.68 3.0 versus 2.6 p=0.01
REACH Zhu et al.9 Ramucirumab 
versus placebo
A 283 versus 282 9.2 versus 7.6 p=0.14 3.5 versus 2.6 p<0.0001




A-B7 424 versus 211 7.8 versus 7.4 p=0.88 2.6 versus 2.6* p=0.075





A 226 versus 114 8.4 versus 8.1 p=0.81 2.4 versus 3 p=0.076
RESORCE Bruix et al.25 Regorafenib 
versus placebo
A 379 versus 194 10.6 versus 7.8 <0.0001 3.9 versus 1.5 <0.0001




A 470 versus 237 10.2 versus 8.0 p=0.005 5.2 versus 1.9* p=0.001
REACH-2 Zhu et al.41 Ramucirumab 
versus placebow
A 197 versus 95 8.5 versus 7.3 p=0.0199 2.8 versus 1.6* p<0.0001
 In patients with baseline MET-high tumor.
w In patients with baseline α-fetoprotein ≥400 ng/mL.
* TTP is not reported, only PFS is available.
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patients were required to have Child-Pugh A or B7 for the dose-
escalation phase and Child-Pugh A for the dose-expansion 
phase and were enrolled into three cohorts on the basis of 
etiology (without viral hepatitis, HCV infection, and HBV 
infection). Although the majority of the patients were heavily 
pretreated, 56 were sorafenib-naïve or intolerant patients. 
Patients received I.V. nivolumab every 2 weeks at 0.1–10 mg/kg 
in the dose-escalation phase (48 patients), and 3 mg/kg in the 
dose-expansion phase (214 patients). Overall, the DCR was 
reached in 64% of the cases (complete response [CR] 1%, PR 
18%, and SD 45%). Responses occurred early in treatment, 
generally within 3 months, and were durable in time (median 
duration of response [DoR] 9.9 months). Survival outcomes 
were encouraging with a 6- and 9-month survival of 83 and 
74%, respectively, and an mTTP of 4 months. In recent updates 
of the study, 18-month OS rates were 57% in sorafenib-naïve 
patients and 44% in sorafenib-experienced patients, mOS was 
28.6 months and 15.6 months, respectively, and survival was 
correlated with the degree of nivolumab antitumor activity.51,52
As for safety, the most common adverse events of any 
grade were fatigue (23%), pruritus (21%), and rash (15%) and 
grade 3/4 AST and alanine aminotransferase (ALT) increase 
occurred in 4 and 2%, respectively. Symptomatic treatment-
related adverse events were comparable in patients with 
and without HCV or HBV infection. As a secondary endpoint, 
PD-L1 expression levels were retrospectively assessed as a 
potential biomarker for nivolumab therapy. Using a cut-off of 
at least 1% of membrane expression of PD-L1 on tumor cells, 
no correlation with outcome was demonstrated. On the basis 
of the Checkmate-040 study, the FDA granted accelerated 
approval for the use of nivolumab in patients previously treated 
with sorafenib. More recently, at the 2018 AASLD meeting, 
results of the Child-Pugh B cohort of the Checkmate-040 study 
were presented: 25 patients were sorafenib naïve and 24 were 
sorafenib experienced, 37 had a B7 Child-Pugh score, while 11 
had a B8. As for efficacy, ORR was 10.2% and DCR was 55.1%, 
with a median DOR of 9.9 months; mOS was 7.6 months. The 
safety profile of nivolumab in patients with Child-Pugh B status 
was comparable to patients with Child-Pugh A status. Drug-
related adverse events led to discontinuation in 2 patients 
(grade 3 hepatic function disorder; grade 2 hyperbilirubinemia 
plus grade 3 transaminase increase, respectively).53
Pembrolizumab
Pembrolizumab was assessed in patients with advanced HCC 
who had progressed on (80%) or were intolerant to (20%) 
sorafenib in the KEYNOTE-224, a nonrandomized, multicenter 
phase II trial. A total of 104 eligible patients were enrolled and 
treated with pembrolizumab 200 mg I.V. every 3 weeks for 
up to 35 cycles.54 After a median follow-up of 12.3 months, 
an ORR was recorded in 18 (17%) of the patients (CR 1% and 
PR 16%). Moreover, 44% of patients had SD as best response 
on treatment. Similar to nivolumab, also for pembrolizumab 
responses generally occurred at the first radiological 
assessment and were durable. The mTTP was 4.9 months, 
while mOS was 12.9 months. The most frequent serious 
adverse events were increased AST concentration in four (4%) 
participants, increased ALT concentration in two (2%), and 
adrenal insufficiency in two (2%) participants. The association 
with tumor proportion score was not significant, consistently 
with Checkmate 040 conclusions. However, to explore potential 
predictive biomarkers, investigators used a combined positive 
score (a measure of PD-L1-positive immune and tumor cell 
number) that was found to be associated with response to 
pembrolizumab.55 Based on the KEYNOTE-224 results, the FDA 
granted accelerated approval for the use of pembrolizumab in 
patients previously treated with sorafenib. Merck has recently 
published a press release about the final analysis of the phase 
III trial KEYNOTE-240 (NCT02702401) evaluating pembrolizumab 
versus placebo as second-line treatment in Western population; 
although the co-primary endpoints OS and PFS were improved, 
these differences did not meet the statistical significance.56
Ongoing and future trials
Final considerations about the role of anti-PD-1 monotherapy 
in HCC will be drawn as soon as other RCTs will be completed; 
the results of the CheckMate-459 and the BGB-A317-301 trials 
(nivolumab or tislelizumab compared with sorafenib in the first-
line setting, NCT02576509, NCT03412773) and of the KEYNOTE 
394 (pembrolizumab versus placebo as second-line setting in 
Asian population, NCT03062358) are eagerly awaited.
In addition, other strategies are being pursued to maximize 
the potential of immunotherapy; in particular, some trials 
are exploring the combination of anti-PD-1/PD-L1 with TKIs, 
anti-VEGF, or anti-CTLA-4. Some results from phase I trials 
are already available, and they show a potential benefit 
compared to anti-PD-1 monotherapy. In a group of 18 subjects 
(6 previously treated and 12 treatment-naive), lenvatinib and 
pembrolizumab yielded high rates of ORR (46% PR) and a 
92% DCR.57 The combination of two checkpoint inhibitors, the 
anti-PD-L1 durvalumab and the anti-CTLA-4 tremelimumab 
given at the dose of 20 and 1 mg/kg I.V., respectively, for 
four doses followed by 20 mg/kg durvalumab alone every 
4 weeks, was tested in a safety run-in cohort with 40 patients. 
No unexpected safety signals were seen in this unresectable 
HCC population that included 30% of sorafenib-naïve patients. 
Clinical activity was observed predominantly in uninfected 
patients (DCR 70 versus 44.4 and 45.5% of HCV and HBV 
infected).58 Taking the advantage of the immunomodulatory 
effects of anti-VEGF therapy, the combination of atezolizumab 
1200 mg and bevacizumab 15 mg/kg every three weeks is 
being explored. Among the 73 patients enrolled in a phase 
Ib trial, ORR was 32% with responses observed in all clinical 
significant subgroups and adverse events were consistent with 
the established safety profile of each agent.59 Atezolizumab 
is also being tested in combination with the anti-glypican-3 
codrituzumab. In the preliminary analyses on 18 patients 
recently reported, the combinations obtained 1 PR and 10 SD, 
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Table 2. Ongoing immunotherapy studies in HCC.




III Phase 3 Study of BGB-A317 versus Sorafenib in Patients with 
Unresectable HCC
NCT03412773 Recruiting
III An Investigational Immuno-therapy Study of Nivolumab 
Compared to Sorafenib as a First Treatment in Patients with 
Advanced Hepatocellular Carcinoma
NCT02576509 Active, not recruiting
III Study of Pembrolizumab (MK-3475) versus Best Supportive 
Care in Participants with Previously Systemically Treated 
Advanced Hepatocellular Carcinoma (MK-3475-240/
KEYNOTE-240)
NCT02702401 Active, not recruiting
III Study of Pembrolizumab (MK-3475) or Placebo Given with 




I/II An Immuno-therapy Study to Evaluate the Effectiveness, Safety 
and Tolerability of Nivolumab or Nivolumab in Combination 
with Other Agents in Patients with Advanced Liver Cancer 
(CheckMate040)
NCT01658878 Active, not recruiting




III Safety and Efficacy of Lenvatinib (E7080/MK-7902) in 
Combination with Pembrolizumab (MK-3475) versus 
Lenvatinib as First-line Therapy in Participants with 
Advanced Hepatocellular Carcinoma (MK-7902-002/LEAP-002)
NCT03713593 Not yet recruiting
III Study of Durvalumab and Tremelimumab as First-line Treatment in 
Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)
NCT03298451 Recruiting
III A Study of Atezolizumab in Combination with Bevacizumab 
Compared with Sorafenib in Patients with Untreated Locally 
Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] 
(IMbrave150)
NCT03434379 Recruiting
I/II A Trial to Evaluate the Safety and Efficacy of the Combination of 
the Oncolytic Immunotherapy Pexa-Vec with the PD-1 Receptor 
Blocking Antibody Nivolumab in the First-line Treatment of 
Advanced HCC
NCT03071094 Recruiting
I/II CBT-501 or Nivolumab in Combination with CBT-101 in Locally 
Advanced or Metastatic HCC and RCC
NCT03655613 Recruiting
II A Study of MEDI4736 with Tremelimumab, MEDI4736 or 
Tremelimumab Monotherapy in Unresectable Hepatocellular 
Carcinoma
NCT02519348 Recruiting
I Study of Safety and Tolerability of PDR001 in Combination with 
Sorafenib and to Identify the Maximum Tolerated Dose and/or 
Phase 2 Dose for This Combination in Advanced Hepatocellular 
Patients
NCT02988440 Recruiting
II A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination with 
Apatinib in Patients with Advanced HCC(RESCUE)
NCT03463876 Recruiting
I/II A Study of Galunisertib (LY2157299) in Combination with 
Nivolumab in Advanced Refractory Solid Tumors and in 
Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
NCT02423343 Recruiting
(Continued)
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Table 2. (Continued)
Phase Title ClinicalTrials.gov 
identifier
Status
I/II Exploratory Clinical Study of Apatinib and SHR-1210 in Treating 
Advanced Hepatocellular Carcinoma or Gastric Cancer
NCT02942329 Recruiting
I/II Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in 
Advanced HCC
NCT02795429 Recruiting
I/Ib Phase I/Ib Study of NIS793 in Combination with PDR001 in 
Patients with Advanced Malignancies
NCT02947165 Recruiting
I A Study of Ramucirumab (LY3009806) Plus MEDI4736 in 
Participants with Advanced Gastrointestinal or Thoracic 
Malignancies
NCT02572687 Active, not recruiting
I/II Study of Cabozantinib in Combination with Atezolizumab to 
Subjects with Locally Advanced or Metastatic Solid Tumors
NCT03170960 Recruiting
I Regorafenib Plus Pembrolizumab in First Line Systemic 
Treatment of HCC
NCT03347292 Recruiting
I/II A Phase I/II Study of Regorafenib Plus Avelumab in Digestive 
Tumors (REGOMUNE)
NCT03475953 Recruiting
I A Study of Avelumab in Combination with Axitinib in 
Advanced HCC (VEGF Liver 100)
NCT03289533 Recruiting
Early stage disease (BCLC A or B)
II Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated 
by Electroporation (NIVOLEP)
NCT03630640 Recruiting
II CTLA-4 /PD-L1 Blockade Following Transarterial 
Chemoembolization (DEB-TACE) in Patients with Intermediate 
Stage of HCC(Hepatocellular Carcinoma) Using Durvalumab and 
Tremelimumab
NCT03638141 Not yet recruiting
I Stereotactic Body Radiotherapy (SBRT) Followed 
by Immunotherapy in Liver Cancer
NCT03203304 Recruiting
I Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus 
Nivolumab (CaboNivo) Followed by Definitive Resection for 
Patients with Locally Advanced Hepatocellular Carcinoma (HCC)
NCT03299946 Recruiting
III A Study of Nivolumab in Patients with Hepatocellular 
Carcinoma Who Are at High Risk of Recurrence after Curative 
Hepatic Resection or Ablation (CheckMate 9DX)
NCT03383458 Recruiting
II Study Evaluating Nivolumab (Anti-PD-1 Antibody) 
Alone versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 
Antibody) in Patients with Resectable and Potentially 
Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
NCT03222076 Recruiting
II Transarterial Chemoembolization in Combination with 
Nivolumab Performed for Intermediate Stage Hepatocellular 
Carcinoma (IMMUTACE)
NCT03572582 Recruiting
II A Study of the Safety and Antitumoral Efficacy of Nivolumab 
After SIRT for the Treatment of Patients with HCC (NASIR-HCC)
NCT03380130 Recruiting
II A Pilot Study of Combined Immune Checkpoint Inhibition 
in Combination with Ablative Therapies in Subjects 
with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas 
(BTC)
NCT02821754 Recruiting
I Pembrolizumab Plus Y90 Radioembolization in HCC Subjects NCT03099564 Recruiting
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was negative for the primary endpoint; in this case, indeed, 
the predictive biomarker, AFP elevation, is a clinical and not a 
molecular biomarker.
It has already been pointed out that the effect of anti-
angiogenic drugs has reached an efficacy ceiling with a mOS 
of first-line treatments constantly below 1 year.64 Although 
much progress has been made, especially in the second-line 
treatment after sorafenib, it is mandatory for clinical research 
to focus on optimizing a treatment algorithm, rather than 
introducing into the market ‘me-too’ drugs. In the absence 
of a direct comparison between second-line options, some 
aspects of the RCTs that we have discussed may be used to help 
clinicians; for example, regorafenib should not be offered to 
patients who are sorafenib intolerant, whereas cabozantinib 
may be used also in third-line treatment. Ramucirumab 
differs from the other treatment options for the route of 
administration (I.V.) and for the presence of a predictive 
biomarker (AFP≥400 ng/mL).
In this context, immunotherapy has drawn considerable 
interest for its potential under many issues. First, its mechanism 
of action is completely different from the other approved  
drugs. Second, although a minority of patients could 
experience severe and even potentially life-threatening 
toxicities, immunotherapy has a more favorable profile 
that makes the combination with other compounds easier 
and that could be exploited in patients with impaired liver 
function. If initial results are confirmed in phase III trials and 
immunotherapy will become a standard of care in first- or 
second-line treatment for HCC, current evidence regarding 
second-line therapy after sorafenib exposure will be difficultly 
applicable. In addition, immunotherapy may produce early 
and durable responses that are already being investigated 
in other disease settings, such as neoadjuvant treatment or 
combination with local treatments increasing tumor antigens 
exposure. The recent announcement of the negative results 
of the KEYNOTE-240 trial might hamper the enthusiasm for 
immunotherapy, but it will be important to analyze the whole 
data to draw definitive conclusions.
Hopefully, with the advances in understanding tumor 
microenvironment and immune reactivity,49 we will be able to 
select patients for their potential response to these new drugs.
some of which are durable.60 The ongoing immunotherapy 
studies, both for advanced and for early–intermediate stage 
disease, are reported in Table 2.
Discussion
Advanced HCC still is a medical unmet need; for over a 
decade, sorafenib had been the only approved treatment in 
this setting, with several drugs failing to show a benefit both 
in first- and second-line setting in RCTs.61 Trials conducted 
in the last decade have been generally characterized by an 
underestimation of driving mechanisms of HCC pathogenesis 
and progression; thus, many studies enrolled a heterogeneous 
population regardless of potential biomarkers of response. 
Similarly, promising drugs were moved from phase II to phase 
III on the basis of very small, single-arm trials and relying on 
surrogate endpoints such as ORR, PFS, and TTP that are not 
predictors of OS in HCC. In patients with compromised baseline 
liver function due to chronic liver disease, the toxicity of certain 
drugs might strongly impact on treatment compliance and 
efficacy. In addition, it has to be pointed out that trials generally 
enroll patients with Child-Pugh A liver function that are not 
representative of all HCC patients. As a consequence, scientific 
evidence of safety for Child-Pugh B patients that could be 
treated in clinical practice is always limited to observational or 
retrospective series. In a recently presented real-life experience 
after first-line sorafenib, investigators remarked that only a 
small proportion of patients (13.1%) met the criteria used for 
enrollment in RESORCE, CELESTIAL, and REACH-2 trials. By 
using modified eligibility criteria (such as including patients 
with ECOG PS 2 or with Child-Pugh score B7), the percentage 
of eligible patients would increase to 31.7%, but at the cost of a 
worse survival outcome62 (mOS 6.2 versus 9.4 months of strict 
eligibility criteria).
Although the molecular underpinnings of HCC are being 
unveiled, the majority of recurrent somatic genetic alterations 
are not directly druggable63; unsurprisingly, the larger part 
of the recently approved drugs were tested in a ‘all-comers’ 
setting and block, among the others, the VEGF pathway. 
Ramucirumab is actually the only drug that has proven 
efficacy in a biomarker-selected population, thanks to an 
initial preplanned subgroup analysis from the REACH trial that 
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